Advanced search
Publication Cover
Expert Review of Gastroenterology & Hepatology Volume 4, 2010 - Issue 4
Submit an article Journal homepage
60
Views
12
CrossRef citations to date
0
Altmetric
Review

Hepatitis C virus recurrence after liver transplantation: biomarkers of disease and fibrosis progression

Daniel G Maluf Virginia Commonwealth University, VA, USA; Transplant Division, Virginia Commonwealth University Medical Center, Medical College of Virginia Hospitals, 1200 East Broad Street, West Hospital, 9th Fl, South Wing, PO Box 980254, Richmond, VA 23298, USA;[email protected]
,
Kellie J Archer Virginia Commonwealth University, VA, USA; Transplant Division, Virginia Commonwealth University Medical Center, Medical College of Virginia Hospitals, 1200 East Broad Street, West Hospital, 9th Fl, South Wing, PO Box 980254, Richmond, VA 23298, USA; Virginia Commonwealth University, VA, USA; Transplant Division, Virginia Commonwealth University Medical Center, Medical College of Virginia Hospitals, 1200 East Broad Street, West Hospital, 9th Fl, South Wing, PO Box 980254, Richmond, VA 23298, USA
,
Federico Villamil Hospital Britanico de Buenos Aires, Buenos Aires, Argentina; Hospital Britanico de Buenos Aires, Buenos Aires, Argentina
,
Richard Todd Stravitz Virginia Commonwealth University, VA, USA; Transplant Division, Virginia Commonwealth University Medical Center, Medical College of Virginia Hospitals, 1200 East Broad Street, West Hospital, 9th Fl, South Wing, PO Box 980254, Richmond, VA 23298, USA; Virginia Commonwealth University, VA, USA; Transplant Division, Virginia Commonwealth University Medical Center, Medical College of Virginia Hospitals, 1200 East Broad Street, West Hospital, 9th Fl, South Wing, PO Box 980254, Richmond, VA 23298, USA
&
Valeria Mas Virginia Commonwealth University, VA, USA; Transplant Division, Virginia Commonwealth University Medical Center, Medical College of Virginia Hospitals, 1200 East Broad Street, West Hospital, 9th Fl, South Wing, PO Box 980254, Richmond, VA 23298, USA; Virginia Commonwealth University, VA, USA; Transplant Division, Virginia Commonwealth University Medical Center, Medical College of Virginia Hospitals, 1200 East Broad Street, West Hospital, 9th Fl, South Wing, PO Box 980254, Richmond, VA 23298, USA
Pages 445-458 | Published online: 10 Jan 2014

References

  • Alter MJ. Epidemiology of hepatitis C. Hepatology26, S62–S65 (1997).
  • Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver diseases in the United States: summary of a workshop. Hepatology36, 227–242 (2002).
  • Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl.9, 331–338 (2003).
  • Garcia-Retortillo M, Forns X, Feliu A et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology35, 680–687 (2002).
  • Laskus T, Radkowski M, Wilkinson J, Vargas H, Rakela J. The origin of hepatitis C virus reinfecting transplanted livers: serum-derived versus peripheral blood mononuclear cell-derived virus. J. Infect. Dis.185, 417–421 (2002).
  • Ducoulombier D, Roque-Afonso AM, Di Liberto G et al. Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes. Hepatology39, 817–825 (2004).
  • Blasco A, Forns X, Carrion JA et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology43, 492–499 (2006).
  • Neumann UP, Berg T, Bahra M et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J. Hepatol.41, 830–836 (2004).
  • Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl.9, S1–S9 (2003).
  • Futagawa Y, Terasaki PI, Waki K, Cai J, Gjertson DW. No improvement in long-term liver transplant graft survival in the last decade: an analysis of the UNOS data. Am. J. Transplant.6, 1398–1406 (2006).
  • Garcia-Retortillo M, Forns X, Feliu A et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology35, 680–687 (2002).
  • Fukumoto T, Berg T, Ku Y et al. Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions. Hepatology24, 1351–1354 (1996).
  • Moll C, Kähler C, Edis C et al. Early-level hepatitis C viremia after orthotopic liver transplantation is of prognostic significance. Transplant. Proc.30, 698–700 (1998).
  • Yilmaz N, Shiffman ML, Stravitz RT et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl.13, 975–983 (2007).
  • Prieto M, Berenguer M, Rayón JM et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology29, 250–256 (1999).
  • Alsatie M, Chalasani N, Kwo PY. Management of hepatitis C infection after liver transplantation. Drugs67, 871–885 (2007).
  • Garcia-Retortillo M, Forns X, Feliu A et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology35, 680–687 (2002).
  • Fukumoto T, Berg T, Ku Y et al. Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions. Hepatology24, 1351–1354 (1996).
  • Moll C, Kähler C, Edis C et al. Early-level hepatitis C viremia after orthotopic liver transplantation is of prognostic significance. Transplant. Proc.30, 698–700 (1998).
  • Gane EJ, Portmann BC, Naoumov NV et al. Long-term outcome of hepatitis C infection after liver transplantation. N. Engl. J. Med.334, 815–820 (1996).
  • Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology122, 889–896 (2002).
  • Pelletier SJ, Iezzoni JC, Crabtree TD, Hahn YS, Sawyer RG, Pruett TL. Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necroinflammatory activity. Liver Transpl.6, 44–53 (2000).
  • Prieto M, Berenguer M, Rayón JM et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology29, 250–256 (1999).
  • Slapak GI, Saxena R, Portmann B et al. Graft and systemic disease in long-term survivors of liver transplantation. Hepatology2, 195–202 (1997).
  • Berenguer M, Prieto M, San Juan F et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology36, 202–210 (2002).
  • Berenguer M, Rayón JM, Prieto M et al. Are posttransplantation protocol liver biopsies useful in the long term? Liver Transpl.7, 790–796 (2001).
  • Féray C, Caccamo L, Alexander GJ et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology117, 619–625 (1999).
  • Sánchez-Fueyo A, Restrepo JC, Quintó L et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation73, 56–63 (2002).
  • Berenguer M, Ferrell L, Watson J et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J. Hepatol.32, 673–684 (2000).
  • Domínguez-Gil B, Morales JM. Transplantation in the patient with hepatitis C. Transpl. Int.22(12), 1117–1131 (2009).
  • Roche B, Samuel D. Risk factors for hepatitis C recurrence after liver transplantation. J. Viral. Hepat.14(Suppl. 1), 89–96 (2007).
  • Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J. Hepatol.35, 666–678 (2001).
  • Pruthi J, Medkiff KA, Esrason KT et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl.7, 811–815 (2001).
  • Bruno R, Sacchi P, Puoti M et al. Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection. J. Acquir. Immune Defic. Syndr.46(3), 297–303 (2007).
  • Roche B, Samuel D. Risk factors for hepatitis C recurrence after liver transplantation. J. Viral. Hepat.14(Suppl. 1), 89–96 (2007).
  • Zekry A, Bishop GA, Bowen DG et al. Intrahepatic cytokine profiles associated with posttransplantation hepatitis C virus-related liver injury. Liver Transpl.8, 292–301 (2002).
  • Ryder SD, Irving WL, Jones DA et al. Trent Hepatitis C Study Group. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut53, 451–455 (2004).
  • Shiffman ML. Natural history and risk factors for progression of hepatitis C virus disease and development of hepatocellular cancer before transplantation. Liver Transpl.9, S14–S19 (2003).
  • Wright M, Goldin R, Fabre A et al. HENCORE collaboration. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut52, 574–579 (2003).
  • Firpi RJ, Abdelmalek MF, Soldevila-Pico C et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl.10, 1240–1247 (2004).
  • Gallegos-Orozco JF, Yosephy A, Noble B et al. Natural history of post-liver transplantation hepatitis C: a review of factors that may influence its course. Liver Transpl.15(12), 1872–1881 (2009).
  • Abdelmalek MF, Firpi RJ, Soldevila-Pico C et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl.10, 199–207 (2004).
  • Chalasani N, Manzarbeitia C, Ferenci P et al.; Regasys Transplant Study Group. Peginterferon α-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology41, 289–298 (2005).
  • McCaughan GW, Zekry A. Pathogenesis of hepatitis C virus recurrence in the liver allograft. Liver Transpl.8(10,Suppl. 1), S7–S13 (2002).
  • Schluger LK, Sheiner PA, Thung SN et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology23, 971–976 (1996).
  • Dixon LR, Crawford JM. Early histologic changes in fibrosing cholestatic hepatitis C. Liver Transpl.13(2), 219–226 (2007).
  • McCaughan GW, Zekry A. Effects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection. Transpl. Infect. Dis.2, 166–185 (2000).
  • Arenas JI, Vargas HE, Rakela J. The use of hepatitis C-infected grafts in liver transplantation. Liver Transpl.9, S48–S51 (2003).
  • Ramírez S, Pérez-Del-Pulgar S, Forns X. Virology and pathogenesis of hepatitis C virus recurrence. Liver Transpl.14(Suppl. 2), S27–S35 (2008).
  • Weston SJ, Leistikow RL, Reddy KR et al. Reconstitution of hepatitis C virus-specific T-cell mediated immunity after liver transplantation. Hepatology41(1), 72–81 (2005).
  • Schirren CA, Jung MC, Gerlach JT et al. Liver-derived hepatitis C virus (HCV)-specific CD4+ T cells recognize multiple HCV epitopes and produce interferon γ. Hepatology32, 597–603 (2000).
  • Russo M, Firpi R, Nelson D, Schoonhoven R, Shretha R, Fried M. Early hepatic stellate cell activation is associated with advance fibrosis after liver transplantation in recipients with hepatitis C. Liver Transpl.11, 1235–1241 (2005).
  • Berenguer M, Aguilera V, Prieto M et al. Delayed onset of sever hepatitis C-related liver damage following liver transplantation: a matter of concern? Liver Transpl.9, 1152–1158 (2003).
  • Thuluvath PJ, Guidinger MK, Fung JJ et al. Liver transplantation in the United States, 1999–2008. Am. J. Transplant.10, 1003–1019 (2010).
  • Mutimer DJ, Gunson B, Chen J et al. Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus. Transplantation81, 7–14 (2006).
  • Afdhal NH. Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests? Hepatology37, 972–974 (2003).
  • Dienstag J. The role of liver biopsy in chronic hepatitis C. Hepatology36, S152–S160 (2002).
  • Samuel D, Forns X, Berenguer M et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12–14, 2006). J. Hepatol.45, 127–143 (2006).
  • Benlloch S, Heredia L, Barquero C et al. Prospective validation of a noninvasive index for predicting liver fibrosis in hepatitis C virus-infected liver transplant recipients. Liver Transpl.15(12), 1798–1807 (2009).
  • Pungpapong S, Nunes DP, Krishna M et al. Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C. Liver Transpl.14(9), 1294–1302 (2008).
  • Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am. J. Gastroenterol.102, 2589–2600 (2007).
  • Bosch J, Abraldes JG, Berzigotti A, García-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat. Rev. Gastroenterol. Hepatol.6(10), 573–582 (2009)
  • Russo MW, Firpi RJ, Nelson DR, Schoonhoven R, Shrestha R, Fried MW. Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C. Liver Transpl.11(10), 1235–1241 (2005).
  • Sawyers CL. The cancer biomarker problem. Nature452(7187), 548–552 (2008).
  • van’t Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature452(7187), 564–570 (2008).
  • Neusser MA, Lindenmeyer MT, Kretzler M, Cohen CD. Genomic analysis in nephrology – towards systems biology and systematic medicine? Nephrol. Ther.4(5), 306–311 (2008).
  • Kurian S, Grigoryev Y, Head S, Campbell D, Mondala T, Salomon DR. Applying genomics to organ transplantation medicine in both discovery and validation of biomarkers. Int. Immunopharmacol.7(14), 1948–1960 (2007).
  • Knechtle SJ, Kwun J. Unique aspects of rejection and tolerance in liver transplantation. Semin. Liver Dis.29(1), 91–101 (2009).
  • Burton JR Jr, Rosen HR. Acute rejection in HCV-infected liver transplant recipients: the great conundrum. Liver Transpl.12(11 Suppl. 2), S38–S47 (2006).
  • Manousou P, Samonakis D, Cholongitas E et al. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. Liver Transpl.15(12), 1783–1791 (2009).
  • Gelb B, Feng S. Management of the liver transplant patient. Expert Rev. Gastroenterol. Hepatol.3(6), 631–647 (2009).
  • Regev A, Molina E, Moura R et al. Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation. Liver Transpl.10(10), 1233–1239 (2004).
  • Schmeding M, Dankof A, Krenn V et al. C4d in acute rejection after liver transplantation – a valuable tool in differential diagnosis to hepatitis C recurrence. Am. J. Transplant.6(3), 523–530 (2006).
  • Jain A, Ryan C, Mohanka R et al. Characterization of CD4, CD8, CD56 positive lymphocytes and C4d deposits to distinguish acute cellular rejection from recurrent hepatitis C in post-liver transplant biopsies. Clin. Transplant.20(5), 624–633 (2006).
  • Cabrera R, Ararat M, Soldevila-Pico C et al. Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients. Liver Transpl.15(2), 216–222 (2009).
  • Rubinas T, Dellon E, Henel G. Use of an immune functional assay to differentiate recurrent hepatitis C from acute cellular rejection in liver transplant patients. Liver Transpl.15(9), 1157 (2009).
  • Hashimoto K, Miller C, Hirose K et al. Measurement of CD4+ T-cell function in predicting allograft rejection and recurrent hepatitis C after liver transplantation. Clin. Transplant. DOI: 10.1111/j.1399-0012.2009.01169.x (2009) (Epub ahead of print).
  • Khatri P, Sarwal MM. Using gene arrays in diagnosis of rejection. Curr. Opin. Organ Transplant.14(1), 34–39 (2009).
  • Ying L, Sarwal M. In praise of arrays. Pediatr. Nephrol.24(9), 1643–1659; quiz 1655, 1659 (2009).
  • Weintraub LA, Sarwal MM. Microarrays: a monitoring tool for transplant patients? Transpl. Int.19(10), 775–788 (2006).
  • Sreekumar R, Rasmussen DL, Wiesner RH, Charlton MR. Differential allograft gene expression in acute cellular rejection and recurrence of hepatitis C after liver transplantation. Liver Transpl.8, 814–821 (2002).
  • Macquillan GC, de Boer WB, Allan JE, Platten MA, Reed WD, Jeffrey GP. Hepatocellular MxA protein expression supports the differentiation of recurrent hepatitis C disease from acute cellular rejection after liver transplantation. Clin. Transplant.24(2), 252–258 (2010).
  • Mas V, Maluf D, Archer K, Stravitz RT, Posner M, Fisher RA. HCV recurrence post-transplantation: molecular pathways affected in the allograft. Presented at: 15th Annual International Congress. NY, USA, 8–11 July 2009.
  • Asaoka T, Kato T, Marubashi S et al. Differential transcriptome patterns for acute cellular rejection in recipients with recurrent hepatitis C after liver transplantation. Liver Transpl.15(12), 1738–1749 (2009).
  • Micheloud D, Salcedo M, Bañares R et al. Serum levels of fibrosis biomarkers measured early after liver transplantation are associated with severe hepatitis C virus recurrence. Transpl. Infect. Dis.11(2), 183–188 (2009).
  • Carrión JA, Fernández-Varo G, Bruguera M et al. Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. Gastroenterology138(1), 147–158.e1 (2010).
  • Smith MW, Walters KA, Korth MJ et al. Gene expression patterns that correlate with hepatitis C and early progression to fibrosis in liver transplant recipients. Gastroenterology130(1), 179–187 (2006).
  • Carpentier A, Conti F, Stenard F et al. Increased expression of regulatory Tr1 cells in recurrent hepatitis C after liver transplantation. Am. J. Transplant.9(9), 2102–2112 (2009).
  • Mas V, Maluf D, Potter A, Archer K, Suh JL, Descalzi V, Villamil F. Genomics analysis of formalin-fixed paraffin embedded liver biopsies to predict severity of HCV recurrence. Presented at: 15th Annual International Congress. NY, USA, 8–11 July 2009.
  • Burra P. Hepatitis C. Semin. Liver Dis.29(1), 53–65 (2009).
  • D’Errico-Grigioni A, Fiorentino M, Vasuri F et al. Tissue hepatitis C virus RNA quantification and protein expression help identify early hepatitis C virus recurrence after liver transplantation. Liver Transpl.14(3), 313–320 (2008).
  • Grassi A, Quarneti C, Ravaioli M et al. Detection of HCV antigens in liver graft: relevance to the management of recurrent post-liver transplant hepatitis C. Liver Transpl.12(11), 1673–1681 (2006).
  • Unitt E, Gelson W, Davies SE et al. Minichromosome maintenance protein-2-positive portal tract lymphocytes distinguish acute cellular rejection from hepatitis C virus recurrence after liver transplantation. Liver Transpl.15(3), 306–312 (2009).
  • Corradi F, Piscaglia F, Flori S et al. Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: usefulness of transient elastography. Dig. Liver Dis.41(3), 217–225 (2009).
  • Harada N, Soejima Y, Taketomi A et al. Assessment of graft fibrosis by transient elastography in patients with recurrent hepatitis C after living donor liver transplantation. Transplantation85(1), 69–74 (2008).
  • Carrión JA, Fernández-Varo G, Bruguera M et al. Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. Gastroenterology138(1), 147–158 (2010).
  • Toniutto P, Fabris C, Bitetto D et al. Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation. J. Gastroenterol. Hepatol.22(11), 1904–1908 (2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.